KROS

Keros Therapeutics, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-04

Figures on this page computed 2026-11-08 13:21 UTC

Last close

10.83USD

Market data, 2026-11-04

KROS: weekly closes from 10.10 on 2026-08-14 to 10.83 on 2026-11-04, a move of +7.2%. Prices in USD.

Weekly closes, 2026-08-14 to 2026-11-04

Over that span: +7.2%

Except where said otherwise: 10-K for 2025, filed 2026-03-04

4.0xP/E
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001664710-26-000018
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-04
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001664710-26-000018
Reported in
USD
- 10-K for 2025, filed 2026-03-04
- 10-K for 2025, filed 2026-03-04
- 10-K for 2025, filed 2026-03-04
- 10-Q for 2025, filed 2026-08-03
- 10-K for 2025, filed 2026-03-04
- 10-Q for 2025, filed 2026-08-03
The filing itself
35.7%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001664710-26-000018
Reported in
USD
- 10-K for 2025, filed 2026-03-04
- 10-K for 2025, filed 2026-03-04
The filing itself
43.5%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001664710-26-000018
Reported in
USD
- 10-K for 2025, filed 2026-03-04
- 10-K for 2025, filed 2026-03-04
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001664710-26-000018
Reported in
USD
- 10-K for 2025, filed 2026-03-04
- 10-Q for 2025, filed 2026-08-03
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

5 of 6 traits placed on the market's range. Nothing sits below its sector's middle.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

6.87x

-1.46x

-2.32x

n/a

0.29x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

4 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-04

Sales6.87x
Its own average over 8 years, 35.5M.
Profit-1.46x
Its own average over 8 years, -59.5M.
Free cash flow-2.32x
Its own average over 8 years, -45.6M.
Debtn/a
Its own average over 2 years, 9.8M.
Price0.29x
Its own average over 7 years, 38. Market data, 2026-11-04

Sales is furthest from its own average, at 6.87 times.

A find tonight

The earnings in its last filed year are 24.6 percent of what the whole company costs, the free cash flow it filed is 29.9 percent of its market value, and sits at 6.53 on Altman's Z, clear of the distress band; it is in none of the indexes we carry (Dow Jones Industrial Average, Nasdaq-100 and S&P 500).

Value: 74
Cheap: 91
Sound: 58
Unwatched: 67

What stands out

Safety: sits at 6.53 on Altman's Z, clear of the distress band, which is better than 83 percent of the companies we rank in United States.
Price: the earnings in its last filed year are 24.6 percent of what the whole company costs, which is better than 98 percent of the companies we rank in United States.

Why nobody is looking

It is in none of the indexes we carry (Dow Jones Industrial Average, Nasdaq-100 and S&P 500).

What could make it a trap

It is down 30.4 percent over the last year, and the market may be reading something the last filing does not show.

Why it is cheap

Except where said otherwise: Computed from the filing for 2025, filed 2026-03-04

Earnings yield24.6%
Filed net income for the last annual period, over market value
Source
computed
Fiscal year
2025
Taken on
2026-11-06
Reported in
USD
- 10-K for 2025, filed 2026-03-04
- Market data, 2026-11-06
Free cash flow yield29.9%
Filed operating cash flow less capital expenditure, over market value
Source
computed
Fiscal year
2025
Taken on
2026-11-06
Reported in
USD
- 10-K for 2025, filed 2026-03-04
- Market data, 2026-11-06
Price to book1.2x
Market value over filed total equity
Source
computed
Fiscal year
2025
Taken on
2026-11-06
Reported in
USD
- 10-K for 2025, filed 2026-03-04
- Market data, 2026-11-06
Cash and equivalents against market value81.1%
Filed cash and equivalents, over market value
Source
computed
Fiscal year
2025
Taken on
2026-11-06
Reported in
USD
- 10-K for 2025, filed 2026-03-04
- Market data, 2026-11-06
Altman Z-Score6.5310-K for 2025, filed 2026-03-04
Source
filed
Statement
income
Fiscal year
2025
Accession
0001664710-26-000018
Reported in
USD
Piotroski F-Score5.0010-K for 2025, filed 2026-03-04
Source
filed
Statement
income
Fiscal year
2025
Accession
0001664710-26-000018
Reported in
USD
Earnings quality (Sloan accruals)1.0610-K for 2025, filed 2026-03-04
Source
filed
Statement
income
Fiscal year
2025
Accession
0001664710-26-000018
Reported in
USD
Consecutive profitable filed years110-K for 2025, filed 2026-03-04
Source
filed
Statement
income
Fiscal year
2025
Accession
0001664710-26-000018
Reported in
USD

Last close: Market data, 2026-11-06

The filed years, as a table

Each line is 100 at 2018-12-31, the first year we hold.

Filed year	Sales	Shares in issue
2018-12-31	100.0	100.0
2019-12-31	100.0	n/a
2020-12-31	0.0	174.6
2021-12-31	201.0	262.7
2022-12-31	0.0	284.2
2023-12-31	1.5	331.5
2024-12-31	0.0	421.5
2025-12-31	2,438.6	426.2

How sales was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001664710-26-000018
Reported in: USD

The filing itself

How shares in issue was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001664710-26-000018
Reported in: USD

The filing itself

Figures behind the shape

Growth

146.4%

faster is higher, placed against 4,950 companies as of 2026-11-07

Five-year revenue growth raten/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Five-year EPS growth raten/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
One-year change in net income146.4%
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Returns on capital

28.7%

higher is higher, placed against 5,089 companies as of 2026-11-07

Return on invested capitaln/a
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001664710-26-000018
Reported in
USD
- 10-K for 2025, filed 2026-03-04
- 10-K for 2025, filed 2026-03-04
- 10-K for 2025, filed 2026-03-04
- 10-Q for 2025, filed 2026-08-03
- 10-K for 2025, filed 2026-03-04
- 10-Q for 2025, filed 2026-08-03
The filing itself
Return on equity28.7%
Net Income / Shareholders' Equity x 100
Source
computed
Fiscal year
2025
Accession
0001664710-26-000018
Reported in
USD
- 10-K for 2025, filed 2026-03-04
- 10-Q for 2025, filed 2026-08-03
The filing itself
Return on assets25.7%
Net Income / Total Assets x 100
Source
computed
Fiscal year
2025
Accession
0001664710-26-000018
Reported in
USD
- 10-K for 2025, filed 2026-03-04
- 10-Q for 2025, filed 2026-08-03
The filing itself

Margins

27.7%

wider is higher, placed against 3,412 companies as of 2026-11-07

Gross marginn/a
We do not hold this figure for this company, so there is nothing to place.
Gross Profit / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001664710-26-000018
Reported in
USD
- 10-K for 2025, filed 2026-03-04
- 10-K for 2025, filed 2026-03-04
The filing itself
Operating margin27.7%
Operating Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001664710-26-000018
Reported in
USD
- 10-K for 2025, filed 2026-03-04
- 10-K for 2025, filed 2026-03-04
The filing itself
Net margin35.7%
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001664710-26-000018
Reported in
USD
- 10-K for 2025, filed 2026-03-04
- 10-K for 2025, filed 2026-03-04
The filing itself
Free cash flow margin43.5%
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001664710-26-000018
Reported in
USD
- 10-K for 2025, filed 2026-03-04
- 10-K for 2025, filed 2026-03-04
The filing itself

Price

4.0x

cheaper is higher, placed against 4,362 companies as of 2026-11-07

Price to earnings4.0x
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001664710-26-000018
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-04
The filing itself
Price to book1.2x10-Q for 2025, filed 2026-08-03
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001664710-26-000049
Reported in
USD
- computed
- 10-Q for 2025, filed 2026-08-03
- computed
- 10-K for 2025, filed 2026-03-04
The filing itself
EV to EBITDAn/a
We do not hold this figure for this company, so there is nothing to place.
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001664710-26-000018
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-04
- 10-K for 2025, filed 2026-03-04
- 10-Q for 2025, filed 2026-08-03
- 10-K for 2025, filed 2026-03-04
The filing itself
Price to sales ratio1.4x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001664710-26-000018
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-04
- 10-K for 2025, filed 2026-03-04
The filing itself

Safety

15.45

safer is higher, placed against 3,227 companies as of 2026-11-07

Debt to equityn/a
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001664710-26-000018
Reported in
USD
- 10-K for 2025, filed 2026-03-04
- 10-Q for 2025, filed 2026-08-03
The filing itself
Current ratio15.4510-Q for 2025, filed 2026-08-03
Current Assets / Current Liabilities
Source
computed
Fiscal year
2025
Accession
0001664710-26-000049
Reported in
USD
- 10-Q for 2025, filed 2026-08-03
- 10-Q for 2025, filed 2026-08-03
The filing itself
Interest coveragen/a
We do not hold this figure for this company, so there is nothing to place.
Operating Income / Interest Expense
Source
computed
Fiscal year
2025
Accession
0001664710-26-000018
Reported in
USD
- 10-K for 2025, filed 2026-03-04
- 10-K for 2025, filed 2026-03-04
The filing itself
Altman Z-Score6.53
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
Source
computed
Taken on
2026-11-07
Reported in
USD
- Computed from the 10-K for 2025, filed 2026-03-04
- Computed from the 10-K for 2025, filed 2026-03-04
- Computed from the 10-K for 2025, filed 2026-03-04
- Computed from the 10-K for 2025, filed 2026-03-04
- Computed from the 10-K for 2025, filed 2026-03-04

What it pays out

n/a

We do not hold this figure for this company, so there is nothing to place.

more, and better covered, is higher, with no cohort held

Dividend yieldn/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Payout ration/a
We do not hold this figure for this company, so there is nothing to place.
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
Source
computed
Fiscal year
2025
Accession
0001664710-26-000018
Reported in
USD
- 10-K for 2025, filed 2026-03-04
- Computed from the 10-K for 2025, filed 2026-03-04
- 10-K for 2025, filed 2026-03-04
The filing itself
Dividend cover ration/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Share a finding

A link to the finding, not to you: it carries nothing about your account.